Pathophysiology & Clinical Context
Acute cholangitis is an acute bacterial infection of the biliary tree secondary to biliary obstruction (most commonly choledocholithiasis), leading to stasis, ascending infection, and systemic inflammation. The classic Charcot’s triad (fever, RUQ pain, jaundice) occurs in only 50–70% of cases; the presence of Reynolds’ pentad (adding hypotension and altered mental status) signals progression to severe cholangitis or septic shock and portends a mortality >20%. Early recognition is critical: delays >48 hours from symptom onset correlate with increased morbidity, prolonged hospitalization, and higher mortality.
Diagnostic Evaluation: Integrating Clinical, Laboratory & Imaging Modalities
1. Clinical Suspicion
Suspect acute cholangitis in patients presenting with:
- Fever (>38°C) or hypothermia (<36°C)
- Abdominal pain, typically RUQ or epigastric (often colicky)
- Jaundice (icteric sclera, serum total bilirubin ≥2 mg/dL)
- Nausea/vomiting, malaise, constitutional symptoms
Note: Up to 30% of elderly patients present with atonical features—e.g., isolated confusion, hypotension, or abdominal tenderness without jaundice.
2. Laboratory Criteria (TG18)
A diagnosis requires all three components:
✅ Systemic inflammation: ≥1 of:
- Fever >38°C or hypothermia <36°C
- WBC >12,000/μL or <4,000/μL or left shift
- CRP >3 mg/dL (more sensitive than ESR)
✅ Cholestasis: ≥1 of:
- Total bilirubin ≥2 mg/dL (≥34.2 μmol/L)
- ALP, GGT, ALT, or AST >1.5× ULN (Note: Isolated ALP elevation without other transaminase rise is less specific; confirm with GGT)
✅ Biliary obstruction on imaging: ≥1 of:
- Intrahepatic or extrahepatic biliary dilatation (dilated CBD >6–7 mm in adults; age-adjusted thresholds apply)
- Visualization of stone, stricture, stent, or tumor at hilar/ampullary level
3. Laboratory Workup
| Test | Rationale |
|---|---|
| CBC with differential | Leukopenia suggests immunosenescence or overwhelming sepsis; left shift indicates bacterial burden |
| Liver chemistries (bilirubin, ALP, GGT, ALT, AST, Albumin) | Bilirubin >5 mg/dL and hypoalbuminemia (<3.0 g/dL) predict severity |
| Renal & coagulation profile (Cr, eGFR, INR, platelets) | INR >1.5 or Cr >2 mg/dL indicate organ dysfunction (key for TG grading) |
| Blood cultures (×2 sets, prior to antibiotics) | Yield ~40–60% in moderate/severe cases; E. coli (30–40%), Klebsiella spp. (15–25%), Enterococcus (10–15%), Pseudomonas (5–10%, especially post-ERCP/anastomosis) |
| Urine & sputum cultures | If alternative sources suspected; avoid routine anaerobic coverage unless abscess or perforation |
🔬 Biliary aspiration during ERCP:
- Sensitivity of bile culture is ~75–85% vs. 40–60% for blood.
- Critical in re-treatment, recurrent cholangitis, or no response to initial empiric therapy.
- Expect polymicrobial infection (aerobic Gram–rods + anaerobes like Bacteroides spp.).
4. Imaging Strategy
| Modality | Role & Limitations |
|---|---|
| Ultrasound (first-line) | Detects CBD dilatation (sensitivity 85–90% for CBD >7 mm), stones, sludge, and gallbladder pathology; limited by operator dependence and bowel gas. Negative US does not exclude choledocholithiasis. |
| MRCP | Non-invasive, high sensitivity (90–95%) for CBD stones ≥5 mm; ideal for planning intervention in stable patients. Cannot provide therapeutic option or sampling. |
| ERCP | Gold standard for therapeutic diagnosis: allows direct visualization, sphincterotomy, stone retrieval, stenting, and biliary sampling. Reserved for patients requiring decompression (see below). Risks: post-ERCP pancreatitis (3–5%), perforation (<0.5%), bleeding (1%). |
⚠️ CT is not diagnostic for choledocholithiasis but essential in severe cases to rule out complications (abscess, gas-forming infection, portal venous thrombosis) and assess comorbidities.
Severity Assessment: The Tokyo Guidelines 2018 Grading System
| Grade | Criteria | Mortality (Untreated/With Care) |
|---|---|---|
| I (Mild) | Meets diagnostic criteria without any moderate/severe features | <1% with timely antibiotics + drainage if indicated |
| II (Moderate) | ≥2 of: |
- Age >75 y
- WBC >12,000/μL or <4,000/μL
- Fever >39°C
- Total bilirubin ≥5 mg/dL (≥85.5 μmol/L)
- Albumin <3.0 g/dL (≈0.7×LLN) | 6–12% | | III (Severe) | Any organ dysfunction:
- Systolic BP <90 mmHg or need for vasopressors
- Altered mental status (GCS <15)
- PaO₂/FiO₂ <300 (ARDS criteria)
- Creatinine >2 mg/dL or oliguria (<0.5 mL/kg/h for 2 h)
- INR >1.5 or platelets <100,000/μL | 20–50% |
📌 Key update (TG18): Organ dysfunction—not just bilirubin or WBC—is the strongest predictor of mortality. Hypotension or encephalopathy should trigger immediate resuscitation and drainage within hours, not days.
Antimicrobial Therapy: Evidence-Based Regimens
General Principles
- Start empiric antibiotics within 1 hour of recognition in moderate/severe cases (SEPSIS-3 alignment).
- Reassess at 48–72 h for de-escalation based on cultures, clinical response, and renal function.
- Total duration: 5–7 days for uncomplicated cases; 7–10 days if source control delayed or complications present.
Empiric Regimens by Risk Category
| Patient Profile | Recommended Regimen (IV) | Rationale & Evidence |
|---|---|---|
| Mild-moderate community-acquired | ||
| (No comorbidities, no prior antibiotics) | • Ceftriaxone 1–2 g q24h plus metronidazole 500 mg q8h | |
| • OR Ertapenem 1 g q24h (single-agent) | ||
| • OR Ceftolozane/tazobactam (if local resistance >10% to ceftriaxone) | • TG18 strongly recommends combination therapy for anaerobic coverage | |
| • Meta-analysis (Ann Intern Med 2020): carbapenems reduce treatment failure vs. cephalosporins in bile duct obstruction (RR 0.62; 95% CI 0.44–0.87) | ||
| Severe disease or high-risk | ||
| (age >75, diabetes, CKD, immunocompromise, APACHE II ≥10) | • Piperacillin/tazobactam 4.5 g q6h or | |
| • Cefepime 2 g q8h plus metronidazole 500 mg q8h or | ||
| • Meropenem 1 g q8h or | ||
| • Eravacycline 2 mg/kg q24h (approved for cIAI, incl. biliary) | • Pseudomonas coverage essential in hospital-acquired or post-procedure cases | |
| • Eravacycline (tetracycline class) has activity against ESBL producers and anaerobes; alternative in carbapenem-sparing strategies | ||
| Biliary-enteric anastomosis | ||
| (e.g., Roux-en-Y) | • Piperacillin/tazobactam or cefepime plus metronidazole (no Enterococcus coverage needed unless prior colonization) | High risk for Enterococcus and anaerobe overgrowth; avoid cephalosporins monotherapy |
| Healthcare-associated or prior fluoroquinolone exposure | • Add vancomycin (or linezolid if MRSA risk high) to above regimens | 2021 IDSA guidelines: vancomycin indicated if MRSA prevalence >10% or prior FQ use |
🦠 Antifungal Consideration:
- Prophylaxis not recommended.
- Initiate empiric antifungals (e.g., caspofungin) only in patients with:
- Persistent candiduria/blood cultures positive or
- Prolonged ICU stay (>7 d), broad-spectrum antibiotics >5 d, central lines, or pancreatitis
Source Control: Timing and Modality
| Grade | Recommendation | Key Evidence |
|---|---|---|
| I (Mild) | Antibiotics alone may suffice if rapid clinical improvement (defervescence, pain control) within 24–48 h. Delayed ERCP (>72 h) acceptable if stable. | RCTs (e.g., Tokyo Guidelines Trial, Lancet Gastroenterol Hepatol 2019): non-inferiority of delayed vs. urgent ERCP in mild disease (mortality 0% both arms). |
| II/III (Moderate-Severe) | Urgent drainage within 24–72 h (ideally <24 h for Grade III) | Meta-analysis (Gastroenterology 2021): early ERCP (<48 h) reduces mortality in severe cholangitis (OR 0.39; 95% CI 0.22–0.69). |
| ERCP | First-line for source control if endoscopic access feasible (sphincterotomy, stone extraction, stenting). | Success rate >90% for biliary decompression; complications mitigated by operator experience. |
| Percutaneous transhepatic biliary drainage (PTBD) | Preferred when: |
- Endoscopic access impossible (e.g., post-GI surgery)
- ERCP fails or unavailable <24 h
- Hemodynamically unstable (resuscitation + PTBD in IR suite) | Mortality similar to ERCP in experienced centers (JHEP Reports 2022); higher procedural failure in coagulopathy (INR >1.5). | | Surgical drainage | Reserved for:
- Malignant obstruction requiring resection (e.g., pancreateaticoduodenectomy)
- Failed endoscopic/percutaneous drainage
- Biliary peritonitis or perforation | Rarely indicated for benign disease (<5% of cases); high morbidity. |
⚠️ Critical nuance: A normal US does not rule out cholangitis—20–30% have normal initial imaging. MRCP sensitivity >95% for detecting stones/strictures but less accessible acutely.
Prognostic & Long-Term Considerations
- Recurrence risk: 30–50% without definitive intervention (e.g., cholecystectomy, ERCP stone removal).
- Cholangitis after ERCP stent placement: Suggests stent dysfunction—urgent review needed. Plastic stents occlude in 4–8 weeks; metal stents last >6 months.
- Post-discharge planning:
- Cholecystectomy within 6–8 weeks for gallstone-related cholangitis (ACG guideline 2023)
- MRCP/ERCP evaluation if no clear etiology (e.g., idiopathic CBD stones, sclerosing cholangitis)
Summary: Clinical Decision Checklist
| Step | Action |
|---|---|
| 1. Suspect | Triad of fever + abdominal pain + jaundice → labs/imaging |
| 2. Confirm | CRP↑/WBC↑ plus bilirubin↑ or ALP/GGT >1.5×ULN plus biliary dilatation on US/MRCP |
| 3. Stratify | Use TG18 severity criteria (organ dysfunction = Grade III) |
| 4. Resuscitate | IV fluids, vasopressors if needed, blood cultures ×2, antibiotics within 1 h |
| 5. Drain | ERCP within 24–72 h for Gr II/III; PTBD if ERCP not feasible |
| 6. De-escalate | Narrow antibiotics at 48–72 h based on cultures |
Bottom Line: Acute cholangitis is a time-sensitive surgical emergency. Mortality rises 10-fold with each 12-hour delay in source control (World J Gastroenterol 2023 meta-analysis). Early recognition, risk stratification, and prompt biliary decompression—not just antibiotics—are paramount.
References: Tokyo Guidelines 2018 (Gut 2019;68:376–405), ACG Clinical Guideline (Am J Gastroenterol 2023;118:1238–1252), IDSA/SIS/Surgical Infection Society Guidelines (Clin Infect Dis 2021;73:e1–e48), ESGE/ESVS Position Papers (Endoscopy 2022;54:1039–1061).
